Arbutus Biopharma (ABUS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates ...

Is Arbutus Biopharma (ABUS) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

*Estimated payments are calculated by Cars.com and are for informational purposes only. We’ve estimated your taxes based on your provided ZIP code. These estimates do not include title ...

Vancouver Mayor Ken Sim lists the extension of TransLink’s Broadway subway from Arbutus Street to the University of B.C. as “one of the most critical transportation priorities for our region.” ...

A lot has happened since I last put Arbutus Biopharma Corporation (NASDAQ:ABUS) in the spotlight early last summer. This clinical stage biopharma concern. Arbutus laid off approximately 40% of its ...

Arbutus is also exiting its corporate headquarters in Pennsylvania and will terminate all in-house scientific research. The company’s focus is now an RNAi asset for hepatitis B. Arbutus Biopharma is ...

Arbutus Biopharma Co. has a 52-week low of $2.30 and a 52-week high of $4.73. Arbutus Biopharma ( NASDAQ:ABUS – Get Free Report ) last issued its earnings results on Thursday, March 27th.

Today, a brief rundown of news involving Novo Nordisk and DBV Technologies, as well as updates from Arbutus Biopharma, Bicycle Therapeutics and CRISPR Therapeutics that you may have missed. This ...

Along with its Q4 2024 financials on Thursday, antiviral developer Arbutus Biopharma (NASDAQ:ABUS) announced plans to reduce its workforce by 57% as part of a broader restructuring program ...

March 27, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today ...